Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease

Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease

Leptomeningeal disease (LMD) is a serious cancer complication associated with poor prognosis. Approximately 5%–25% of patients with melanoma develop LMD. Currently, no standard treatment protocol exists and very few cases have been reported. Despite ongoing advances in new therapies, treatment optio...

Full description

Bibliographic Details
Main Authors: Xiang Dan, Mengxi Huang, Zhaochen Sun, Xiaoyuan Chu, Xin Shi, Yitian Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Oncology
Subjects:
leptomeningeal disease
metastatic melanoma
pembrolizumab
cancer
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1344829/full

Similar Items

Similar Items